Jingning Xu

LncRNA TP73‐AS1 is a novel regulator in cervical cancer via miR‐329‐3p/ARF1 axis

AbstractCervical cancer holds one of the highest morbidity and mortality in various types of cancers. It even leads to the most number of cancer‐related deaths of women. A lot of research has indicated that the anomalous expression of long noncoding RNAs (lncRNAs) would induce carcinogenesis and is associated with poor prognosis of patients with cancer. However, the function and mechanism of many lncRNAs still call for further research. Tumor Protein P73 Antisense RNA 1 (TP73‐AS1) is no exception. LncRNA TP73‐AS1 has been found to promote cancer progressions in various cancers. It is upregulated in cervical cancer cells. The proliferation and migration ability of cervical cancer cells can also be boosted by TP73‐AS1 in return. Meanwhile, miRNA‐329‐3p is downregulated in cervical cancer cells and could bind with both TP73‐AS1 and ADP Ribosylation Factor 1 (ARF1). TP73‐AS1 inhibited miR‐329‐3p expression while miR‐329‐3p inhibited ARF1 expression. More importantly, TP73‐AS1 can positively regulate ARF1 expression. Based on all these experiments, TP73‐AS1 regulates ARF1 expression by competitively binding with miR‐329‐3p, thus regulating cervical cancer progression. Further rescue assays confirmed TP73‐AS1 regulates cervical cell proliferation and migration via miR‐329‐3p/ARF1. TP73‐AS1 might serve as a novel regulator in cervical cancer.